APOLLOHOSP Q4 FY26 Results Analysis: PAT Surges 33%, Digital Health Turns Profitable
APOLLOHOSP reported Q4 FY26 numbers with revenue of Rs. 6,606.00 Cr (+18.12% YoY) and PAT growth of +33.00% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | May 20, 2026 |
|---|---|
| Quarter | Q4 FY 2025-2026 |
| Revenue (Q4) | Rs. 6,606.00 Cr (+18.12% YoY) |
| PAT (Q4) | Rs. 551.30 Cr (+33.00% YoY) |
| EBITDA margin | 15.31% (+155 bps YoY) |
| EPS (Q4) | Rs. 36.82 (+35.87% YoY) |
| Market cap | Rs. 119,230.79 Cr |
| CMP | Rs. 8,313.00 |
Quarter Snapshot
Apollo Hospitals delivered exceptional Q4 FY26 results with revenue growth of 18.12% YoY and PAT surge of 33% YoY, beating management's mid-teens guidance. EBITDA margin expanded 155 bps demonstrating strong operating leverage. The Digital Health segment achieved its first full-year profitability with 490% YoY growth in segment results, validating the path to 7% margin target by Q4 FY27. Free Cash Flow doubled to Rs.8,937 Crore with improved capital structure (Debt/Equity at 0.57x), positioning the company well for sustained growth.
Key Investment Insights
Key Positives
- Revenue grew 18.12% YoY to Rs.6,606 Crore
- PAT to owners surged 33% YoY to Rs.551 Crore
- EBITDA margin expanded 155 bps to 15.31%
- Digital Health segment achieved first full-year profitability
- Retail Health margin surged 516 bps YoY to 8.15%
- Digital Health margin expanded 380 bps to 4.77%
- CFO/PAT ratio strong at 1.43x
- Free Cash Flow doubled to Rs.8,937 Crore
- Debt/Equity improved from 0.61x to 0.57x
- Healthcare Services revenue growth of 17.26% exceeded mid-teens guidance
Risk Factors
- Other expenses grew 21.48% YoY, exceeding revenue growth
- New hospital start-up losses of ~Rs.150 Cr projected over next year
- Healthcare Services margin slightly declined 7 bps YoY to 18.44%
- Working capital impact of Rs.7,703 Million in FY26
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.